Our commitment to keeping you safe

We have never taken for granted the sacred trust you place in us to care for your child, and today we are more grateful than ever for that privilege. To learn about all the ways we are working to keep you, your family and our team members safe, visit our COVID-19 updates page.


The Gill Center’s Lymphoma Program features a team of pediatric oncologists experienced in caring for children with any type of childhood Hodgkin and Non-Hodgkin lymphoma. These experts have access to regional, national and international clinical trials offering the latest treatment therapies – tailoring the therapy to provide the greatest chance to cure each patient. 

What We Treat

We treat all forms of pediatric Hodgkin and Non-Hodgkin lymphoma. As a group, lymphomas represent the third most common childhood cancer. We routinely treat Hodgkin lymphoma, which is the most common cancer in 15- to 19-year-olds, accounting for about 1,200 of the 1,700 cases of childhood lymphoma in the U.S. each year.

Non-Hodgkin lymphomas are a diverse group of malignancies, the more common of which are Burkitt lymphoma, diffuse large B cell lymphoma, and anaplastic large cell lymphoma. The breadth and depth of expertise within our program also allows us to treat patients with even the rarest Non-Hodgkin lymphomas. Over the past few years, we have developed treatment plans for adolescents with primary central nervous system lymphoma, follicular lymphoma, blastic plasmacytoid dendritic cell neoplasm, post- transplant lymphoproliferative diseases and others. 

Program Highlights

  • Between 25 and 30 newly diagnosed patients each year
  • Experience in every form of childhood Hodgkin and non-Hodgkin lymphoma, from the most common to the rarest 
  • Opportunities to receive the most advanced therapies for childhood lymphoma through participation in clinical research 


Beyond Children's Oncology Group clinical trials, we conduct our own research. Current projects include: 

  • Early diagnosis of invasive fungal disease  and fungal prophylaxis in children with acute lymphoblastic and myelogenous leukemia
  • Identifying factors that predict risk for serious infection in children with leukemia 
  • Early phase clinical trials employing  new therapeutic agents to eradicate leukemia cells 
  • Laboratory research efforts at  UT Southwestern to understand  the biology of stem cells from  which leukemia begins  

Lymphoma Doctors and Providers